Drug
Icp 022
Icp 022: highest development phase Phase 3, developed by InnoCare Pharma. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| ICP-022 NCT04578613 | Phase 3 | Chronic Lymphocytic Leukemia |
| ICP-022 NCT03797456 | Phase 2 | MZL |
| ICP-022 NCT04438044 | Phase 2 | PCNSL |
| ICP-022 NCT04305197 | Phase 1/2 | Systemic Lupus Erythematosus |
| ICP-022 NCT03493217 | Phase 1/2 | CLL/SLL |
| ICP-022 NCT03189017 | Phase 1 | Systemic Lupus Erythematosus |
Latest
No recent events.
Follow Icp 022 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.